fentanyl-hameln
adeofarma, uab - fentanilis - injekcinis tirpalas - 50 µg/ml - fentanyl
alustal
stallergenes - standartizuotas alergenų ekstraktas+nestandartizuotas alergenų ekstraktas+standartizuotas alergenų ekstraktas+nestandartizuotas alergenų ekstraktas+standartizuotas alergenų ekstraktas+nestandartizuotas alergenų ekstraktas+standartizuotas alergenų ekstraktas+nestandartizuotas alergenų ekstraktas - injekcinė suspensija - 0,01 ri/ml + 0,01 ki/ml + 0,1 ri/ml + 0,1 ki/ml + 1 ri/ml + 1 ki/ml + 10 ri/ml + 10 ki/ml - various
amiodaron hameln
adeofarma, uab - amjodarono hidrochloridas - injekcinis tirpalas - 50 mg/ml - amiodarone
dobutamine hameln
lex ano, uab - dobutaminas - koncentratas infuziniam tirpalui - 12,5 mg/ml; 250 mg/20 ml - dobutamine
dobutamine hameln
adeofarma, uab - dobutaminas - koncentratas infuziniam tirpalui - 12,5 mg/ml - dobutamine
dobutamine hameln
actiofarma, uab - dobutaminas - koncentratas infuziniam tirpalui - 250 mg/20 ml - dobutamine
rocuronium hameln
lex ano, uab - rokuronio bromidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - rocuronium bromide
rokuronijev bromid hameln
lex ano, uab - rokuronio bromidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - rocuronium bromide
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoraginiai - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
cisatracurium hameln
limedika, uab - cisatrakuris - injekcinis ar infuzinis tirpalas - 2 mg/ml - cisatracurium